Clinical trial
Evaluation of the Safety of Relaxin in Preeclampsia
NCT00333307 · Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies, Industry · Suspended
Key facts
| NCT number | NCT00333307 |
|---|---|
| Title | Evaluation of the Safety of Relaxin in Preeclampsia |
| Official title | A Phase I Randomized, Double-Blind, Placebo-Controlled, Dose-Escalation Study to Evaluate the Safety of Recombinant Human Relaxin (rhRlx) in Subjects With Preeclampsia |
| Lead sponsor | Corthera, Inc.(formerly BAS Medical, Inc.), a member of the Novartis group of companies, Industry |
| Status | Suspended |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Pre-Eclampsia |
| Intervention type | Drug |
| Interventions | recombinant human relaxin |
| Enrollment | 18 |
| Start date | Oct 1, 2006 |
| First posted | Jun 5, 2006 |
| Last update posted | Mar 16, 2010 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: